Capricor Therapeutics (NASDAQ:CAPR – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $60.00 target price on the biotechnology company’s stock. HC Wainwright’s target price points to a potential upside of 90.36% from the company’s current price.
A number of other research analysts have also recently commented on the company. Cantor Fitzgerald set a $62.00 price objective on Capricor Therapeutics and gave the company an “overweight” rating in a report on Friday, March 13th. B. Riley Financial boosted their target price on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Finally, Piper Sandler reissued an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $46.09.
Read Our Latest Report on Capricor Therapeutics
Capricor Therapeutics Stock Performance
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). As a group, equities research analysts forecast that Capricor Therapeutics will post 0.01 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Capricor Therapeutics news, Director Karimah Es Sabar sold 7,529 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $32.00, for a total value of $240,928.00. Following the sale, the director owned 7,529 shares of the company’s stock, valued at $240,928. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Anthony Bergmann sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $31.70, for a total value of $792,500.00. Following the completion of the sale, the chief financial officer directly owned 8,223 shares in the company, valued at approximately $260,669.10. The trade was a 75.25% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 172,529 shares of company stock worth $5,302,440. 9.20% of the stock is owned by corporate insiders.
Institutional Trading of Capricor Therapeutics
A number of large investors have recently modified their holdings of the stock. GSA Capital Partners LLP acquired a new position in Capricor Therapeutics during the 3rd quarter worth approximately $1,555,000. Moody Aldrich Partners LLC acquired a new position in Capricor Therapeutics in the fourth quarter valued at $6,025,000. Pier Capital LLC boosted its stake in Capricor Therapeutics by 35.0% in the third quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock valued at $3,580,000 after acquiring an additional 128,837 shares in the last quarter. AlphaQuest LLC boosted its stake in Capricor Therapeutics by 396.2% in the third quarter. AlphaQuest LLC now owns 30,025 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 23,974 shares in the last quarter. Finally, ProShare Advisors LLC acquired a new position in Capricor Therapeutics in the fourth quarter valued at $203,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.
About Capricor Therapeutics
Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.
The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.
Featured Stories
- Five stocks we like better than Capricor Therapeutics
- Ally Financial Is Back to Basics—And Investors Are Watching
- Navitas Breaks Out on India Deal, Validating High-Power AI Pivot
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
